GHAPPcast: The IL23/IL17 Cascade and Implications in the Pathogenesis of IBD

Thank you to Johnson & Johnson for your support of this GHAPPcast episode.

Welcome to GHAPPcast, the official podcast of Gastroenterology and Hepatology Advanced Practice Providers (GHAPP), where we delve into the latest advancements in GI and liver diseases. In this enlightening episode, host Gabriella McCarty, NP-C, from NorthShore Gastroenterology, explores the intricate role of the IL-23/IL-17 axis in inflammatory bowel disease (IBD). This discussion, supported by Johnson & Johnson, offers invaluable insights into how this immunological pathway influences IBD progression and how targeted therapies are shaping the future of treatment.

Joining the conversation is Allison Krustapentus, NP, from Beth Israel Deaconess Medical Center, an expert in IBD patient care and immunology. Together, they break down the IL-23/IL-17 signaling cascade, explaining its impact on immune-mediated inflammation and how disruptions in this pathway contribute to chronic GI conditions like Crohn’s disease and ulcerative colitis. They discuss how IL-23 promotes Th17 cell differentiation, leading to IL-17-driven inflammation, which, when dysregulated, fuels tissue damage, immune overactivity, and chronic inflammation in IBD.

This episode also highlights the therapeutic implications of targeting the IL-23/IL-17 pathway. With the rise of precision medicine, newer biologics are offering more effective, patient-specific treatments that can slow disease progression and improve patient outcomes. The discussion also covers shared decision-making in patient care, emphasizing the importance of educating patients about their disease and available treatment options.

Subscribe to GHAPPcast on your favorite podcast platform for in-depth discussions on IBD, hepatology, and GI innovations. Visit GHAPP.org, download the GHAPP ACE app and follow us on LinkedIn, YouTube, X (formerly Twitter), and Instagram for our latest updates and expert insights.